PsyPost
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Neuroscience
  • About
No Result
View All Result
Join
My Account
PsyPost
No Result
View All Result
Home Exclusive Mental Health Addiction

A common antidepressant shows promise in treating methamphetamine dependence

by Rebecca McKetin and Shalini Arunogiri
April 7, 2026
Reading Time: 4 mins read
[Adobe Stock]

[Adobe Stock]

Methamphetamine – more commonly known as meth, crystal or ice – is a highly addictive, stimulant drug.

An estimated 7.4 million people in the world are dependent on it or “addicted” to it. They face multiple health risks including paranoia, feeling suicidal, heart problems, strokes, injuries from accidents, and a higher risk of early death.

But there are no medications approved anywhere in the world to treat meth dependence.

Now, a cheap, safe and readily available medicine that has been used to treat depression for years is showing promise. Our trial of mirtazapine, just published in JAMA Psychiatry, shows people who take it cut back their meth use.

Few other options

Australia has one of the highest number of people dependent on meth per capita worldwide.

As there are no medications approved for meth dependence anywhere in the world, we have few treatment options.

Currently available treatment options include counselling, detox or withdrawal and long-stay residential rehabilitation. However, access can be difficult and treatment dropout rates are high. Most people who go to rehab relapse.

More sophisticated treatments offered within the community such as contingency management, which involves setting targets and rewards for meeting them, are more effective but aren’t widely available.

Even though there are no approved medications for methamphetamine use, doctors sometimes prescribe existing medications that have shown promise in clinical trials.

Medications that are prescribed off label include prescription stimulants (methylphenidate, lisdexamfetamine, modafinil), the anti-smoking treatment bupropion, the opioid-blocking drug naltrexone (including in combination with bupropion) and antidepressants.

However, these drugs may not work and may cause unnecessary side effects or safety risks.

How about mirtazapine?

Studies in recent years suggest the antidepressant mirtazapine may provide some hope.

Two studies were conducted in the United States in an outpatient research clinic in San Francisco, California. Both trials found mirtazapine reduced meth use.

These initial trials were conducted a research clinic with a small group of patients (60 and 120 respectively) who were monitored closely. Patients were at risk of HIV: men and transgender women who had sex with men. Women and people with people with depression were excluded.

So our Australian team wanted to know if mirtazapine would have the same benefit if it was used by doctors in community clinics to treat a larger and more diverse group of patients.

What we did and what we found

The Tina Trial recruited a larger and more diverse sample of 339 people dependent on meth from six outpatient clinics in Australia.

At the start of the trial, participants had used meth an average of 22 days out of the previous 28.

Half were randomly assigned to either take home mirtazapine (a 30 milligram tablet daily), or a placebo, for 12 weeks. The researchers then tracked days when participants used meth across the 12-week period.

People who received mirtazapine reduced their meth use by more than people who received the placebo (an average reduction of seven out of 28 days compared with 4.8).

So the comparative advantage of mirtazapine was modest: 2.2 days in use out of 28 days.

This benefit was apparent regardless of whether people had depression at the start of the study.

Although this reduction is small, in the absence of any alternative medication this is an important step forward.

Our research team believes mirtazapine has a direct effect on meth dependence, distinct from its ability to reduce depression.

This implies mirtazapine is acting directly on brain systems involved in drug reward, and might restore function to pathways that long-term meth use can disrupt.

Our study found no unexpected safety issues when using mirtazapine to treat meth dependence. The most common side effects were drowsiness and weight gain.

This isn’t a ‘cure’

Mirtazapine is not an instant “cure” for meth dependence. But in the absence of any approved medications for methamphetamine use worldwide, it is a critical first step in providing a medications to reduce harms from methamphetamine.

Mirtazapine is cheap, safe and readily available. Many doctors are familiar with its use to treat depression.

It is a take-home medication, making it convenient for people to use. So there is no need for daily clinic visits or close medical monitoring.

It is also “off patent”, meaning there are inexpensive generic versions.

In order for mirtazapine to be routinely prescribed for meth dependence outside a clinical trial, regulators would need to approve it for this purpose. This requires research evidence, like that provided by the Tina Trial.

In the meantime, doctors can prescribe mirtazapine off label. Guidelines on the off label prescribing of medications are available from the Royal Australian New Zealand College of Psychiatrists.


Further information on the Tina Trial is available here.

If you have concerns about your own or someone else’s drug or alcohol use, call the National Alcohol and Other Drug Hotline on 1800 250 015. This 24/7 hotline provides free and confidential information and support.The Conversation

 

This article is republished from The Conversation under a Creative Commons license. Read the original article.

TweetSendScanShareSendPin1ShareShareShareShareShare

Follow PsyPost

The latest research, however you prefer to read it.

Daily newsletter

One email a day. The newest research, nothing else.

Google News

Get PsyPost stories in your Google News feed.

Add PsyPost to Google News
RSS feed

Use your favorite reader.

Copy RSS URL
Social media
Support independent science journalism

Ad-free reading, full archives, and weekly deep dives for members.

Become a member

Trending

  • Women want to talk about sex with their close friends more often, study finds
  • Scientists uncover how a tiny reflection of light helps us navigate the social world
  • Over 10 percent of factual claims in Google’s AI search summaries aren’t backed by their cited sources, study finds
  • Inflammation briefly dampens pleasure and the desire to socialize, placebo-controlled study finds
  • Narcissistic parents tend to lean on their children for emotional support, and that is linked to depression later on

Science of Money

  • For male startup founders, average looks may pay off best in the pitch room, according to new Shark Tank study
  • Why struggling with bills feels even worse when you think the economy is booming
  • Feeling stuck in an unwanted work location takes a measurable toll on mental health
  • Why having a self-sacrificing boss can feel like a trap, according to psychology
  • News about shortages only triggers stockpiling when shoppers start searching online, study finds

Recent

  • Loving-kindness meditation fails to beat muscle relaxation for pain or social well-being in online trial
  • Losing childhood weight by adulthood might erase later depression risks
  • Women don’t find deeper-than-average voices more attractive when they can see the man
  • Voters value long-term economic growth more than previously thought, study finds
  • Scientists map a blood protein fingerprint of menopause tied to brain health
  • Social anxiety might not warp how we perceive eye contact
  • In female mice modeling schizophrenia, a single dose of psilocybin restored sensory filtering for days
  • Could psychedelics aid therapy for personality disorders? An unusual case offers a first look
  • Schizophrenia is linked to broad difficulty reading emotions from body language and faces
  • Socially isolated and lonely people tend to be biologically older than their years

PsyPost is a psychology and neuroscience news website dedicated to reporting the latest research on human behavior, cognition, and society. (READ MORE...)

  • Mental Health
  • Neuroimaging
  • Personality Psychology
  • Social Psychology
  • Artificial Intelligence
  • Cognitive Science
  • Psychopharmacology
  • Contact us
  • Disclaimer
  • Privacy policy
  • Terms and conditions

(c) PsyPost Media Inc

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy

(c) PsyPost Media Inc